An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C)
in patients with depression.
The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to
placebo in patients with depression.
The secondary objectives are to evaluate the safety of saredutant, to evaluate the efficacy
of saredutant on disability and quality of life in patients with depression, and to evaluate
blood levels of saredutant.